Table 2.

Descriptive characteristics of the primary study cohort. MRI positive data is shown as the PI-RADS score of ≥ 3 or ≥ 4. Detection rates for cancer are shown for any cancer, and using definitions of ≥ Grade Group 2 (GG2 or ≥ Cambridge Prognostic Group 3 [CPG3]

	≥ GG2 cancer detection	pvalue (vs. PSA)	≥ CPG3 cancer detection	pvalue (vs.PSA)
Whole cohort
PSA	0.70 (0.66–0.74)	–	0.81 (0.78–0.85)	–
PSAd	0.79 (0.75–0.83)	< 0.001	0.84 (0.80–0.87)	0.12
phi	0.82 (0.78–0.85)	< 0.001	0.87 (0.84–0.90)	< 0.001
MRI	0.63 (0.59–0.66)	< 0.001*	0.63 (0.60–0.66)	< 0.001*
MRI + PSA	0.76 (0.72–0.80)	< 0.001	0.85 (0.81–0.88)	0.03
MRI + PSAd	0.81 (0.77–0.84)	< 0.001	0.85 (0.81–0.88)	0.08
MRI + phi	0.81 (0.78–0.85)	< 0.001	0.86 (0.83–0.90)	0.02
MRI negative
PSA	0.64 (0.52–0.76)	–	0.86 (0.76–0.97)	–
PSAd	0.76 (0.64–0.87)	0.01	0.95 (0.91–0.99)	0.08
phi	0.78 (0.66–0.90)	0.01	0.89 (0.74–1.00)	0.76